Overexpression of branched-chain amino acid aminotransferases rescues the growth defects of cells lacking the Barth syndrome-related gene TAZ1
The yeast protein Taz1 is the orthologue of human Tafazzin, a phospholipid acyltransferase involved in cardiolipin (CL) remodeling via a monolyso CL (MLCL) intermediate. Mutations in Tafazzin lead to Barth syndrome (BTHS), a metabolic and neuromuscular disorder that primarily affects the heart, muscles, and immune system. Similar to observations in fibroblasts and platelets from patients with BTHS or from animal models, abolishing yeast Taz1 results in decreased total CL amounts, increased levels of MLCL, and mitochondrial dysfunction. However, the biochemical mechanisms underlying the mitochondrial dysfunction in BTHS remain unclear. To better understand the pathomechanism of BTHS, we searched for multi-copy suppressors of the taz1Δ growth defect in yeast cells. We identified the branched-chain amino acid transaminases (BCATs) Bat1 and Bat2 as such suppressors. Similarly, overexpression of the mitochondrial isoform BCAT2 in mammalian cells lacking TAZ improves their growth. Elevated levels of Bat1 or Bat2 did not restore the reduced membrane potential, altered stability of respiratory complexes, or the defective accumulation of MLCL species in yeast taz1Δ cells. Importantly, supplying yeast or mammalian cells lacking TAZ1 with certain amino acids restored their growth behavior. Hence, our findings suggest that the metabolism of amino acids has an important and disease-relevant role in cells lacking Taz1 function.
Bat1 and Bat2 are multi-copy suppressors of retarded growth of taz1Δ yeast cells.
Overexpression of Bat1/2 in taz1Δ cells does not rescue known mitochondrial defects.
Supplementation of amino acids enhances growth of cells lacking Taz1 or Tafazzin.
Altered metabolism of amino acids might be involved in the pathomechanism of BTSH.
KeywordsBarth syndrome Cardiolipin Mitochondria Tafazzin/TAZ1
We thank E. Kracker for excellent technical assistance, Dr. R. Lill for antibodies, and Dr. K.S. Dimmer for helpful discussions.
This work was supported by the Barth Syndrome Foundation (D.R. and M.S.), the DFG D.I.P. program (D.R., J.M.H., and M.S.), SFB1002 (TP A06, PR), ERC (ERCAdG No. 339580, PR), MWK FoP 88b (PR), and the Max Planck Society (PR). D.A. was supported by the IMPRS “From Molecules to Organisms.”
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
- 9.Chowdhury A, Aich A, Jain G, Wozny K, Lüchtenborg C, Hartmann M, Bernhard O, Balleiniger M, Ahmed Alfar E, Zieseniss A, Toischer K, Guan K, Rizzoli S, Brügger B, Fischer A, Katschinski D, Rehling P, Dudek J (2018) Mitochondrial ROS activate NF-kB in hypoxia to stimulate HIF-1a expression—a signaling process affected by defective cardiolipin-remodeling in Barth syndrome. Cell Rep 25:561–570CrossRefGoogle Scholar
- 12.Daum G, Bohni PC, Schatz G (1982) Import of proteins into mitochondria. Cytochrome b2 and cytochrome c peroxidase are located in the intermembrane space of yeast mitochondria. J Biol Chem 257:13028–13033Google Scholar
- 16.Gebert N, Joshi AS, Kutik S, Becker T, McKenzie M, Guan XL, Mooga VP, Stroud DA, Kulkarni G, Wenk MR, Rehling P, Meisinger C, Ryan MT, Wiedemann N, Greenberg ML, Pfanner N (2009) Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome. Curr Biol 19:2133–2139CrossRefGoogle Scholar
- 17.Gietz RD, Woods RA (2006) Yeast transformation by the LiAc/SS carrier DNA/PEG method. Methods Mol Biol 313:107–120Google Scholar
- 18.Gonzalvez F, D'Aurelio M, Boutant M, Moustapha A, Puech JP, Landes T, Arnaune-Pelloquin L, Vial G, Taleux N, Slomianny C, Wanders RJ, Houtkooper RH, Bellenguer P, Moller IM, Gottlieb E, Vaz FM, Manfredi G, Petit PX (2013) Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation. Biochim Biophys Acta 1832:1194–1206CrossRefGoogle Scholar
- 21.Janke C, Magiera MM, Rathfelder N, Taxis C, Reber S, Maekawa H, Moreno-Borchart A, Doenges G, Schwob E, Schiebel E, Knop M (2004) A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes. Yeast 21:947–962CrossRefGoogle Scholar
- 31.Sauerwald J, Jores T, Eisenberg-Bord M, Chuartzman SG, Schuldiner M, Rapaport D (2015) Genome-wide screens in Saccharomyces cerevisiae highlight a role for cardiolipin in biogenesis of mitochondrial outer membrane multispan proteins. Mol Cell Biol 35:3200–3211Google Scholar
- 35.Stettler S, Chiannilkulchai N, Hermann-Le Denmat S, Lalo D, Lacroute F, Sentenac A, Thuriaux P (1993) A general suppressor of RNA polymerase I, II and III mutations in Saccharomyces cerevisiae. Mol Gen Genet 239:169–176Google Scholar
- 39.Valianpour F, Wanders RJ, Overmars H, Vreken P, Van Gennip AH, Baas F, Plecko B, Santer R, Becker K, Barth PG (2002) Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060): a study in cultured skin fibroblasts. J Pediatr 141:729–733CrossRefGoogle Scholar
- 44.Ye C, Lou W, Li Y, Chatzispyrou IA, Huttemann M, Lee I, Houtkooper RH, Vaz FM, Chen S, Greenberg ML (2014) Deletion of the cardiolipin-specific phospholipase Cld1 rescues growth and life span defects in the tafazzin mutant: implications for Barth syndrome. J Biol Chem 289:3114–3125CrossRefGoogle Scholar